Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care

Speciality: Oncology


Speaker:

Dr. Vamsi Krishna M | Medical Oncology Consultant Medical Oncologist, AIG Hospital

Description:

Welcome to this insightful discussion featuring Dr. Vamshi Krishna M, a renowned expert in oncology, as he delves into the unmet needs and challenges in the current care of ALK-positive Non-Small Cell Lung Cancer (NSCLC). In this video, Dr. Vamshi highlights the significant gaps in treatment options, including resistance mechanisms, limited access to next-generation therapies, and the need for personalized approaches to improve patient outcomes. He emphasizes the importance of early detection, advanced diagnostics, and the development of novel therapeutic strategies to address these pressing issues.

Dr. Vamshi further explores the real-world challenges faced by clinicians managing ALK-positive NSCLC, such as treatment sequencing, managing side effects, and optimizing therapy for better survival rates. He discusses the evolving landscape of targeted therapies and immunotherapy while underscoring the necessity for more clinical trials and collaborative research to bridge existing gaps. His expertise provides valuable perspectives for oncologists, researchers, and healthcare professionals striving to enhance patient care in this niche yet critical area of lung cancer.

Don’t miss this compelling discussion that sheds light on the future directions and unmet needs in ALK-positive NSCLC. Stay tuned for more expert insights from Dr. Vamshi Krishna M and other leading voices in oncology. Be sure to watch till the end and subscribe for updates on upcoming videos that continue to explore groundbreaking advancements in cancer care.


See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.

2.

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

3.

CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma

4.

Virtual Reality Travel Reduces Cancer Pain.

5.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot